CN101686991A - 对降低肾毒性有用的组合物及其使用方法 - Google Patents

对降低肾毒性有用的组合物及其使用方法 Download PDF

Info

Publication number
CN101686991A
CN101686991A CN200880017313A CN200880017313A CN101686991A CN 101686991 A CN101686991 A CN 101686991A CN 200880017313 A CN200880017313 A CN 200880017313A CN 200880017313 A CN200880017313 A CN 200880017313A CN 101686991 A CN101686991 A CN 101686991A
Authority
CN
China
Prior art keywords
mtx
renal
mice
cyclodextrin
oligosaccharide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880017313A
Other languages
English (en)
Chinese (zh)
Inventor
弗农·D.·罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verrow Pharmaceuticals Inc
Original Assignee
Verrow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verrow Pharmaceuticals Inc filed Critical Verrow Pharmaceuticals Inc
Publication of CN101686991A publication Critical patent/CN101686991A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN200880017313A 2007-05-25 2008-05-22 对降低肾毒性有用的组合物及其使用方法 Pending CN101686991A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/753,883 US7658913B2 (en) 2005-11-28 2007-05-25 Compositions useful for reducing nephrotoxicity and methods of use thereof
US11/753,883 2007-05-25
PCT/US2008/064489 WO2008147856A1 (en) 2007-05-25 2008-05-22 Compositions useful for reducing nephrotoxicity and methods of use thereof

Publications (1)

Publication Number Publication Date
CN101686991A true CN101686991A (zh) 2010-03-31

Family

ID=40076731

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880017313A Pending CN101686991A (zh) 2007-05-25 2008-05-22 对降低肾毒性有用的组合物及其使用方法

Country Status (10)

Country Link
US (5) US7658913B2 (enExample)
EP (1) EP2162138B1 (enExample)
JP (1) JP5416095B2 (enExample)
KR (1) KR20100023901A (enExample)
CN (1) CN101686991A (enExample)
AU (1) AU2008256808B2 (enExample)
BR (1) BRPI0812166A2 (enExample)
CA (1) CA2687574C (enExample)
MX (1) MX2009012523A (enExample)
WO (1) WO2008147856A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111419860A (zh) * 2020-03-19 2020-07-17 长春市儿童医院 一种肾小球分叶状肾病造模方法
CN114982708A (zh) * 2022-05-11 2022-09-02 成都医学院第一附属医院 一种小鼠造影剂肾病模型及其构建方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658913B2 (en) * 2005-11-28 2010-02-09 Verrow Pharmaceuticals, Inc. Compositions useful for reducing nephrotoxicity and methods of use thereof
RU2470636C2 (ru) 2007-04-27 2012-12-27 Сайдекс Фамэсьютиклз, Инк. Композиция клопидогреля и сульфоалкилового эфира циклодекстрина (варианты) и способы лечения заболеваний посредством названной композиции (варианты)
US8192721B2 (en) * 2007-12-13 2012-06-05 Verrow Pharmaceuticals, Inc. Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
ES2769949T3 (es) 2009-05-13 2020-06-29 Cydex Pharmaceuticals Inc Composiciones farmacéuticas que comprenden prasugrel y derivados de ciclodextrina y métodos de preparación y uso de las mismas
WO2013180777A1 (en) * 2012-05-30 2013-12-05 Verrow Pharmaceuticals, Inc. Stabilized formulations containing iodinated contrast agents and cyclodextrins
JP6239282B2 (ja) * 2013-06-28 2017-11-29 日本食品化工株式会社 腎不全改善剤
WO2015147018A1 (ja) * 2014-03-28 2015-10-01 テルモ株式会社 炎症性自己免疫疾患治療用の注射用水性製剤
CN104280478B (zh) * 2014-11-03 2016-03-30 天津中医药大学 内源性小分子物质在快速检测肾毒性方面的应用
EP3313519B1 (en) 2015-06-29 2023-05-31 Children's Medical Center Corporation Jak-stat inhibitors for the treatment of congenital myopathies
BR112019023074A2 (pt) * 2017-05-03 2020-06-09 Cydex Pharmaceuticals Inc composição contendo ciclodextrina e bussulfano

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3426011A (en) * 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US4247535A (en) * 1979-11-05 1981-01-27 American Cyanamid Company Modified cyclodextrin sulfate salts as complement inhibitors
US4371673A (en) 1980-07-21 1983-02-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble forms of retinoids
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4654325A (en) * 1984-05-24 1987-03-31 Selenke William M Medicament for reducing nephrotoxicity caused by positively charged agents such as aminoglycosides and methods of use thereof
US4696918A (en) * 1984-11-02 1987-09-29 Johnson Matthey Public Limited Company Solubilized platinum compound
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US4916225A (en) * 1986-11-25 1990-04-10 Institut Organicheskogo Sinteza Akademii Nauk Latviiskoi Ssr 9-substituted guanines
US4877778A (en) * 1987-07-01 1989-10-31 The Children's Medical Center Corporation Method of enhancing lipophile transport using cyclodextrin derivatives
US5441944A (en) * 1989-04-23 1995-08-15 The Trustees Of The University Of Pennsylvania Substituted cyclodextrin sulfates and their uses as growth modulating agents
US5010092A (en) 1989-12-22 1991-04-23 Wisconsin Alumni Research Foundation Protection against chemically-induced kidney damage by methimazole
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
ES2188612T3 (es) * 1993-04-22 2003-07-01 Skyepharma Inc Liposomas multivesiculares de ciclodextrina para encapsular compuestos farmacologicos y metodos para su uso.
US6540981B2 (en) * 1997-12-04 2003-04-01 Amersham Health As Light imaging contrast agents
US5906981A (en) * 1996-06-04 1999-05-25 Troy Corporation Halopropargyl inclusion complexes
US5780446A (en) * 1996-07-09 1998-07-14 Baylor College Of Medicine Formulations of vesicant drugs and methods of use thereof
FR2754270B1 (fr) 1996-10-07 1998-12-24 Goemar Lab Sa Genes codant pour des iota-carraghenases et leur utilisation pour la production d'enzymes de biodegradation des carraghenanes
EP0979097B1 (en) * 1997-03-15 2005-11-02 Nakamura, Toshikazu Hgf for treating acute renal failure
JPH11100401A (ja) * 1997-07-30 1999-04-13 Kikkoman Corp 環状オリゴ糖及びそれを含むレトロウイルス性疾患の予防または治療剤
US6077871A (en) * 1997-11-26 2000-06-20 Pfizer Inc. Droloxifene pharmaceutical compositions
US5994409A (en) * 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
JP3229286B2 (ja) * 1999-04-02 2001-11-19 インターナショナル・ビジネス・マシーンズ・コーポレーション プリント回路基板の製造方法
PT1109806E (pt) * 1999-07-01 2004-02-27 Italfarmaco Spa Complexos de paroxetina com ciclodextrinas ou derivados de ciclodextrinas
GB9921958D0 (en) * 1999-09-16 1999-11-17 Pharmacia & Upjohn Spa Formulations for parenteral use of estramustine phosphate and sulfoalkylether-cyclodextrins
GB9921954D0 (en) 1999-09-16 1999-11-17 Pharmacia & Upjohn Spa Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
KR100358855B1 (ko) * 2000-02-29 2002-10-31 광주과학기술원 사이클로덱스트린 또는 그 유도체와 조영제의 포접 착체형성 방법
KR100362080B1 (ko) 2000-03-29 2002-11-23 광주과학기술원 고리 올리고당과 그들의 유도체를 이용한 조영제의 새로운포접 착체
ATE416791T1 (de) 2000-05-02 2008-12-15 Theravance Inc Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält
US6903100B2 (en) * 2001-05-03 2005-06-07 Midamerica Neuroscience Research Foundation Use of regularly scheduled high dose intravenous methotrexate therapy, with interim administration of immunomodulatory agents, to treat multiple sclerosis and other diseases of the central nervous system
ITMI20012749A1 (it) * 2001-12-21 2003-06-21 Chiesi Farma Spa Procedimento per la preparazione mediante trattamento con microonde di composti di inclusione tra farmaco e ciclodestrine e prodotti ottenut
WO2003080080A1 (en) * 2002-03-21 2003-10-02 Regents Of The University Of Minnesota Cyclodextrin compositions and methods of treating viral infections
NZ570777A (en) 2002-05-17 2009-04-30 Celgene Corp Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
US20040048871A1 (en) * 2002-09-09 2004-03-11 Rowe Vernon D. Use of high dose intravenous methotrexate, with leucovorin rescue, to treat early multiple sclerosis and other diseases of the central nervous system
JP2004235128A (ja) 2002-12-04 2004-08-19 Dainippon Printing Co Ltd 有機ｅｌ素子およびその製造方法
GB0404487D0 (en) * 2004-02-28 2004-03-31 Protherics Molecular Design Lt Use of enzyme
GB0519391D0 (en) * 2005-09-22 2005-11-02 Aion Diagnostics Ltd Imaging agents
US7658913B2 (en) * 2005-11-28 2010-02-09 Verrow Pharmaceuticals, Inc. Compositions useful for reducing nephrotoxicity and methods of use thereof
NZ568288A (en) * 2005-11-28 2012-02-24 Verrow Pharmaceuticals Inc Compositions comprising a a cyclodextrin and a nephrotoxic anticancer drug
JP4008481B2 (ja) * 2006-08-21 2007-11-14 独立行政法人科学技術振興機構 腎臓の薬物排泄機能に関与する有機アニオントランスポーター

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111419860A (zh) * 2020-03-19 2020-07-17 长春市儿童医院 一种肾小球分叶状肾病造模方法
CN114982708A (zh) * 2022-05-11 2022-09-02 成都医学院第一附属医院 一种小鼠造影剂肾病模型及其构建方法

Also Published As

Publication number Publication date
US20070270380A1 (en) 2007-11-22
EP2162138A1 (en) 2010-03-17
BRPI0812166A2 (pt) 2015-07-07
MX2009012523A (es) 2010-02-18
US7658913B2 (en) 2010-02-09
AU2008256808A1 (en) 2008-12-04
US20110027390A1 (en) 2011-02-03
JP2010528045A (ja) 2010-08-19
JP5416095B2 (ja) 2014-02-12
KR20100023901A (ko) 2010-03-04
US8574551B2 (en) 2013-11-05
EP2162138B1 (en) 2013-08-28
US20120321564A1 (en) 2012-12-20
US20110028413A1 (en) 2011-02-03
CA2687574A1 (en) 2008-12-04
AU2008256808A2 (en) 2010-01-07
WO2008147856A1 (en) 2008-12-04
EP2162138A4 (en) 2010-07-28
AU2008256808B2 (en) 2013-07-04
US20100093664A1 (en) 2010-04-15
CA2687574C (en) 2016-04-12
US8277779B2 (en) 2012-10-02

Similar Documents

Publication Publication Date Title
CN101686991A (zh) 对降低肾毒性有用的组合物及其使用方法
US20050164986A1 (en) Use of sulfoalkyl ether cyclodextrin as a preservative
JP2015155462A (ja) 腎毒性の低減に有用な組成物及びその使用方法
JPH07206696A (ja) 化学療法的腫瘍治療の際の又は泌尿生殖器領域内の細胞を保護するためのアジュバント及び薬剤
WO2013026694A1 (en) Pharmaceutical compositions comprising voriconazole
HK1125822B (en) Compositions useful for reducing nephrotoxicity and methods of use thereof
KR100771411B1 (ko) 피리미딘-2,4,6-트리온의 시클로덱스트린 포접 복합체
ES2311220T3 (es) Uso de trioxopirimidina para el tratamiento y prevision de enfermedades inflamatorias bronquiales.
CN107496441A (zh) 环糊精在治疗和/预防脓毒症中的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20100331